178 related articles for article (PubMed ID: 36452500)
1. Case report: A rapid response to immunotherapy in a thoracic SMARCA4-deficient undifferentiated tumor with respiratory failure.
Shi L; Lin L; Ding Y; Zeng Y; Chen X
Front Oncol; 2022; 12():1020875. PubMed ID: 36452500
[TBL] [Abstract][Full Text] [Related]
2. [Thoracic
Xiong Y; Zhang B; Nie LG; Wu SK; Zhao H; Li D; DI JT
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):351-356. PubMed ID: 37042149
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of tislelizumab when combined with etoposide and carboplatin in patients with SMARCA4-deficient undifferentiated thoracic tumor: a case report.
Yang P; Xiong F; Lin Y; Liang P; Tang C
Transl Cancer Res; 2023 Apr; 12(4):1041-1048. PubMed ID: 37180644
[TBL] [Abstract][Full Text] [Related]
4. Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886
[TBL] [Abstract][Full Text] [Related]
5. Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
Gantzer J; Davidson G; Vokshi B; Weingertner N; Bougoüin A; Moreira M; Lindner V; Lacroix G; Mascaux C; Chenard MP; Bertucci F; Davidson I; Kurtz JE; Sautès-Fridman C; Fridman WH; Malouf GG
Oncologist; 2022 Jun; 27(6):501-511. PubMed ID: 35278076
[TBL] [Abstract][Full Text] [Related]
6. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor.
Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study.
Anžič N; Krasniqi F; Eberhardt AL; Tzankov A; Haslbauer JD
Case Rep Oncol; 2021; 14(2):706-715. PubMed ID: 34177520
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
Shinno Y; Yoshida A; Masuda K; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y
Clin Lung Cancer; 2022 Jul; 23(5):386-392. PubMed ID: 35618627
[TBL] [Abstract][Full Text] [Related]
9. Thorahcic SMARCA4-deficient undifferentiated tumors with ganglioneuroma and enchondroma: implications for SLC7A11 and ARID1A expression: a case report.
Kito Y; Kawashima K; Saigo C; Hasegawa M; Nomura S; Mikamo T; Hanamatsu Y; Matsuo Y; Takeuchi T
Diagn Pathol; 2022 Feb; 17(1):29. PubMed ID: 35151345
[TBL] [Abstract][Full Text] [Related]
10. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.
Nambirajan A; Jain D
Semin Diagn Pathol; 2021 Sep; 38(5):83-89. PubMed ID: 34147303
[TBL] [Abstract][Full Text] [Related]
11. Thoracic SMARCA4-deficient undifferentiated tumor.
Jiang J; Chen Z; Gong J; Han N; Lu H
Discov Oncol; 2023 Apr; 14(1):51. PubMed ID: 37115343
[TBL] [Abstract][Full Text] [Related]
12. Thoracic SMARCA4-deficient undifferentiated tumor with associated granulomatous reaction and response to pembrolizumab.
Marshall M; Khader S; Beasley S; Lajara S
Diagn Cytopathol; 2023 Oct; 51(10):E287-E293. PubMed ID: 37350425
[TBL] [Abstract][Full Text] [Related]
13. A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure.
Ito S; Asahina H; Yamaguchi N; Tomaru U; Hasegawa T; Hatanaka Y; Hatanaka KC; Taguchi H; Harada T; Ohira H; Ikeda D; Mizugaki H; Kikuchi E; Kikuchi J; Sakakibara-Konishi J; Shinagawa N; Konno S
Respir Med Case Rep; 2021; 32():101364. PubMed ID: 33665078
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma.
Kawachi H; Kunimasa K; Kukita Y; Nakamura H; Honma K; Kawamura T; Inoue T; Tamiya M; Kuhara H; Nishino K; Mizote Y; Akazawa T; Tahara H; Kumagai T
Immunotherapy; 2021 Jul; 13(10):799-806. PubMed ID: 34030451
[TBL] [Abstract][Full Text] [Related]
15. Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report.
Kunimasa K; Okami J; Takenaka S; Honma K; Kukita Y; Nagata S; Kawamura T; Inoue T; Tamiya M; Kuhara H; Nishino K; Tahara H; Kumagai T
JTO Clin Res Rep; 2021 Nov; 2(11):100235. PubMed ID: 34746887
[TBL] [Abstract][Full Text] [Related]
16. Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.
Takada K; Sugita S; Murase K; Kikuchi T; Oomori G; Ito R; Hayasaka N; Miyanishi K; Iyama S; Ikeda H; Kobune M; Emori M; Kato J; Hasegawa T
Thorac Cancer; 2019 Dec; 10(12):2312-2315. PubMed ID: 31617320
[TBL] [Abstract][Full Text] [Related]
17. Thoracic SMARCA4-Deficient Undifferentiated Tumor With
Sheng J; Han W; Pan H
JTO Clin Res Rep; 2023 Apr; 4(4):100476. PubMed ID: 36969551
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211
[TBL] [Abstract][Full Text] [Related]
19. Thoracic SMARCA4-Deficient Undifferentiated Tumors With Unusual Presentations: A Case Series.
Helmink AJ; Alshomrani A; Lauer SR; Yuil-Valdes A
Int J Surg Pathol; 2023 Oct; ():10668969231206350. PubMed ID: 37903457
[TBL] [Abstract][Full Text] [Related]
20. SMARCA4-Deficient Undifferentiated Tumor of the Esophagus: Diagnostic Pitfalls in Immunohistochemical Profiles.
Chakrabarti R; Lin S; Wang H; Cecchini M
Int J Surg Pathol; 2024 Mar; ():10668969241228290. PubMed ID: 38497146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
